Exclusive Summary

• - Global exclusivity has expired; since 2016–2018 the US/EU have been open to generics, enabling rapid distribution without patent barriers.
• - Targets high-value inpatient MRSA indications (bacteremia/right-sided endocarditis and cSSTI) with guideline-backed use and steady demand.
• - Dual strengths (350 mg and 500 mg) support weight-based dosing and pediatrics, reducing pharmacy waste and total treatment cost.
• - US and EU-27 registrations demonstrate FDA/EMA-level quality and compliance, facilitating reliance pathways and tender participation across markets.
• - Post-LOE pricing typically 60–80% below the originator, materially lowering multi-week therapy costs in hospital care.